文献速递儿童呼吸儿童感染儿童消化与营养

儿童口服糖皮质激素冲击治疗与严重不良事件的关联

Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children.
PubMed 文献 · JAMA Pediatr · 2021-01-01

该研究基于台湾全民健康保险研究数据库,采用自身对照病例系列设计,分析2013至2017年18岁以下儿童。结果显示,冲击开始后5-30天内胃肠道出血、脓毒症和肺炎风险增加1.4-2.2倍,31-90天风险减弱;青光眼无显著关联。

要点

  • 儿童口服糖皮质激素冲击后30天内胃肠道出血、脓毒症、肺炎风险升高。
  • 风险在31-90天随访期减弱,青光眼未见显著关联。
  • 常见适应症为急性呼吸道感染和过敏性疾病,需权衡获益与风险。

核心结论

  • 儿童口服糖皮质激素冲击与开始治疗后第一个月内胃肠道出血、脓毒症和肺炎风险增加1.4至2.2倍相关。
  • 上述风险在后续31至90天期间减弱。
  • 青光眼与糖皮质激素冲击无显著关联。

研究设计与样本

  • 纳入对象为18岁以下儿童,采用自身对照病例系列设计。
  • 数据分析时间为2020年1月1日至7月30日。

主要发现

  • 单次冲击与未处方糖皮质激素儿童相比,每1000人年的发病率差异为:胃肠道出血0.60(95%CI 0.55-0.64),脓毒症0.03(95%CI 0.02-0.05),肺炎9.35(95%CI 9.19-9.51),青光眼0.01(95%CI 0.01-0.03)。
  • 冲击开始后5至30天内的发病率比(IRR)为:胃肠道出血1.41(95%CI 1.27-1.57),脓毒症2.02(95%CI 1.55-2.64),肺炎2.19(95%CI 2.13-2.25),青光眼0.98(95%CI 0.85-1.13)。
  • 后续31至90天内的IRR为:胃肠道出血1.10(95%CI 1.02-1.19),脓毒症1.08(95%CI 0.88-1.32),肺炎1.09(95%CI 1.07-1.11),青光眼0.95(95%CI 0.85-1.06)。

关键数值与推荐

  • 口服糖皮质激素冲击定义为口服糖皮质激素使用≤14天。
  • 主要结局为胃肠道出血、脓毒症、肺炎和青光眼4种严重不良事件。
  • 采用条件固定效应泊松回归估计冲击开始后5-30天和31-90天内的发病率比。

临床怎么用

  • 儿科医生对呼吸道和过敏性疾病儿童处方糖皮质激素冲击时,应警惕第一个月内胃肠道出血、脓毒症和肺炎风险。
  • 需权衡糖皮质激素冲击的获益与严重不良事件风险,尤其对于常见适应症如急性呼吸道感染和过敏性疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The adverse effects from the long-term use of oral corticosteroids are known, but, to our knowledge, few studies have reported the risk of corticosteroid bursts, particularly among children. OBJECTIVE: To quantify the associations of corticosteroid bursts with severe adverse events, including gastrointestinal (GI) bleeding, sepsis, pneumonia, and glaucoma, in children. DESIGN, SETTING, AND PARTICIPANTS: This study used data derived from the National Health Insurance Research Database in Taiwan from January 1, 2013, to December 31, 2017, on children younger than 18 years of age and used a self-controlled case series design. Data were analyzed from January 1 to July 30, 2020. EXPOSURE: Oral corticosteroid bursts (defined as oral corticosteroid use for ≤14 days). MAIN OUTCOMES AND MEASURES: Incidence rates were calculated of 4 severe adverse events (GI bleeding, sepsis, pneumonia, and glaucoma) in children who did or did not receive corticosteroid bursts. Conditional fixed-effect Poisson regression was used to estimate incidence rate ratios (IRRs) of severe adverse events within 5 to 30 days and 31 to 90 days after initiation of corticosteroid bursts. RESULTS: Among 4 542 623 children, 23% (1 064 587; 544 268 boys [51.1%]; mean [SD] age, 9.7 [5.8] years) were prescribed a single corticosteroid burst. The most common indications were acute respiratory tract infections and allergic diseases. The incidence rate differences per 1000 person-years between children administered a single corticosteroid burst and those not prescribed corticosteroids were 0.60 (95% CI, 0.55-0.64) for GI bleeding, 0.03 (95% CI, 0.02-0.05) for sepsis, 9.35 (95% CI, 9.19-9.51) for pneumonia, and 0.01 (95% CI, 0.01-0.03) for glaucoma. The IRRs within 5 to 30 days after initiating corticosteroid bursts were 1.41 (95% CI, 1.27-1.57) for GI bleeding, 2.02 (95% CI, 1.55-2.64) for sepsis, 2.19 (95% CI, 2.13-2.25) for pneumonia, and 0.98 (95% CI, 0.85-1.13) for glaucoma; the IRRs within the subsequent 31 to 90 days were 1.10 (95% CI, 1.02-1.19) for GI bleeding, 1.08 (95% CI, 0.88-1.32) for sepsis, 1.09 (95% CI, 1.07-1.11) for pneumonia, and 0.95 (95% CI, 0.85-1.06) for glaucoma. CONCLUSIONS AND RELEVANCE: This study suggests that corticosteroid bursts, which are commonly prescribed for children with respiratory and allergic conditions, are associated with a 1.4- to 2.2-fold increased risk of GI bleeding, sepsis, and pneumonia within the first month after initiation of corticosteroid therapy that is attenuated during the subsequent 31 to 90 days.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Yao TC, Wang JY, Chang SM, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. 2021. PMID: 33871562. doi:10.1001/jamapediatrics.2021.0433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。